NASDAQ: TLSATiziana Life Sciences Ltd Stock
$0.84+0.01 (+1.2%)
Updated Mar 24, 2023
TLSA Price
$0.84
Fair Value Price
$1.11
Market Cap
$85.91M
52 Week Low
$0.50
52 Week High
$1.15
P/E
-3.5x
P/B
2.08x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$23.42M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$22M
Beta
0.21
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TLSA Overview
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TLSA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TLSA ($0.84) is undervalued by 24.51% relative to our estimate of its Fair Value price of $1.11 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
TLSA ($0.84) is significantly undervalued by 24.51% relative to our estimate of its Fair Value price of $1.11 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
TLSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TLSA due diligence checks available for Premium users.
Be the first to know about important TLSA news, forecast changes, insider trades & much more!
TLSA News
Valuation
TLSA fair value
Fair Value of TLSA stock based on Discounted Cash Flow (DCF)
Price
$0.84
Fair Value
$1.11
Undervalued by
24.51%
TLSA ($0.84) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TLSA ($0.84) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TLSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TLSA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.5x
Industry
17.88x
Market
21.37x
TLSA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.08x
Industry
4.89x
TLSA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TLSA's financial health
Profit margin
Revenue
$0.0
Net Income
-$23.4M
Profit Margin
0%
TLSA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$48.8M
Liabilities
$7.5M
Debt to equity
0.18
TLSA's short-term assets ($48.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TLSA's short-term assets ($48.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TLSA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TLSA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.8M
Investing
$130.0k
Financing
-$23.0k
TLSA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TLSA vs Biotech Stocks
Tiziana Life Sciences Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.